2 papers
Company2 trialsPhase 2393 people
Company2 trialsPhase 1/232 people
Woodinville Psychiatric Associates
1 trialPhase 261 people
National Institute of Neurological Disorders and Stroke
1 trial1,273 people
VA Office of Research and Development
1 trial10 people
In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.
Estimated annual cognitive decline was 0.007 points in the third reporting the most physical activity time, versus 0.478 points in the third reporting the least.Estimated annual cognitive decline was 0.007 points in the third reporting the most physical activity time, versus 0.478 points in the third reporting the least.
Lewy body disease prevalence rose from 0.7% in individuals younger than 50 to 20.0% in those aged 90 and older across 2,480 autopsied human brains.Lewy body disease prevalence rose from 0.7% in individuals younger than 50 to 20.0% in those aged 90 and older across 2,480 autopsied human brains.